Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 7

Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

,

Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.